Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Oncolytic virotherapy for ovarian cancer

In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients w...

Oncolytic Virotherapy in Cancer

Oncolytic viruses are natural or genetically modified viral species that selectively infect and kill neoplastic cells. Oncolytic viruses as highly targeted agents that would mediate cancer cell-autonomous anticancer effects. The therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect, but strongly relies on the induction of an endogenous immune respon...

Oncolytic virotherapy of ovarian cancer

Personalized virotherapy in cancer

adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment. The high resistance to conventional and targeted therapies in PDAC as in other desmoplastic tumors of adults is largely due to the dense extracellular mat...

Oncolytic virotherapy.

Oncolytic virotherapy is an emerging technology that uses engineered viruses to treat malignancies. Viruses can be designed with biological specificity to infect cancerous cells preferentially, and to replicate in these cells exclusively. Malignant cells may be killed directly by overwhelming viral infection and lysis, which releases additional viral particles to infect neighboring cells and di...